Literature DB >> 28295234

Adverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics.

A A Elzagallaai1,2,3, Mje Greff1,3, M J Rieder1,2,3,4.   

Abstract

Adverse drug reactions (ADRs) represent a major health problem worldwide, with high morbidity and mortality rates. ADRs are classified into Type A (augmented) and Type B (bizarre) ADRs, with the former group being more common and the latter less common but often severe and clinically more problematic due to their unpredictable nature and occurrence at any dose. Pediatric populations are especially vulnerable to ADRs due to the lack of data for this age group from the drug development process and because of the wide use of off-label and unlicensed use of drugs. Children are more prone to specific types of ADRs because of the level of maturity of body systems involved in absorption, metabolism, transportation, and elimination of drugs. This state-of-the-art review provides an overview of definitions, classifications, epidemiology, and pathophysiology of ADRs and discusses the available evidence for related risk factors and causes of ADRs in the pediatric population.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28295234     DOI: 10.1002/cpt.677

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

1.  Active Extraction of Experience of Adverse Drug Reactions in Children.

Authors:  Aoi Noda; Taku Obara; Michihiro Satoh; Naoto Yagi; Nariyasu Mano; Kenji Kaneko
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

Review 2.  Barriers to Drug Distribution into the Perinatal and Postnatal Brain.

Authors:  Jean-François Ghersi-Egea; Elodie Saudrais; Nathalie Strazielle
Journal:  Pharm Res       Date:  2018-03-07       Impact factor: 4.200

3.  Ranitidine-induced Thrombocytopenia in a Neonate - A Case Report and Review of Literature.

Authors:  Levi Hoste; Isabel George
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Jan-Feb

4.  Phenytoin intoxication associated with omeprazole administration in a child with defective CYP2C9.

Authors:  M Marano; F Nicoletti; S Pro; B M Goffredo; C Cecchetti; E Piervincenzi; E Agolini; D Cocciadiferro
Journal:  Eur J Clin Pharmacol       Date:  2020-01-15       Impact factor: 2.953

5.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

Review 6.  Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.

Authors:  David Gregornik; Daria Salyakina; Marilyn Brown; Samuel Roiko; Kenneth Ramos
Journal:  Pharmacogenomics J       Date:  2020-08-26       Impact factor: 3.550

Review 7.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

8.  Fluoroquinolone Antibiotics and Tendon Injury in Adolescents.

Authors:  Rachael K Ross; Alan C Kinlaw; Mackenzie M Herzog; Michele Jonsson Funk; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2021-05-14       Impact factor: 9.703

9.  Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List.

Authors:  Rachel S Meyers; Jennifer Thackray; Kelly L Matson; Christopher McPherson; Lisa Lubsch; Robert C Hellinga; David S Hoff
Journal:  J Pediatr Pharmacol Ther       Date:  2020

10.  Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital.

Authors:  Pritmohinder S Gill; Feliciano B Yu; Patricia A Porter-Gill; Bobby L Boyanton; Judy C Allen; Jason E Farrar; Aravindhan Veerapandiyan; Parthak Prodhan; Kevin J Bielamowicz; Elizabeth Sellars; Andrew Burrow; Joshua L Kennedy; Jeffery L Clothier; David L Becton; Don Rule; G Bradley Schaefer
Journal:  J Pers Med       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.